{"name":"Oryzon Genomics S.A.","slug":"oryzon-genomics-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ORY-2001 Low dose","genericName":"ORY-2001 Low dose","slug":"ory-2001-low-dose","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ORY-2001 Low dose","genericName":"ORY-2001 Low dose","slug":"ory-2001-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNZDdDaVBxRjd1T09oV3pOTlpMYXFCNFFNQW10a25Fel92N3B2NGhpSjk3dC1yTXM1ZVEtbU1IVUFzWkdJTHVXMFo0V1RsVnl4YkZmc1E4bC0zb3lZc1Z6bnNRQnV5T0ZfY2JSQWpzR3l2Rm1TdE9JTFVBMklPclc1WEVhaUt2WF9IMDROSGhPb1pud2U5OFJfS3llWWdUYzFmWUUtM2FJSlRUdml1MHRFZGVrcDVfVlRVNXQwaVZmUTV5cVEyUm1UMngtSU52c3Q0eFFhajBQeEFtcmRDZ2o5UTlZYUpONVlWWVdYUjIzcGZHYjZt?oc=5","date":"2026-02-27","type":"earnings","source":"globenewswire.com","summary":"ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025 - globenewswire.com","headline":"ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxOejVRNW1vTDhaN2FWbmYwTldWTTI0S21keHdHMXRVY2stb24yUzA2Mi00OC0xQ19zNGlxdTUyV3NfYnFGdklaRGdDSG13N2FBdmdqTkhYRk85M1hEcTZWUUppa3RiWDFmWmZvTzRiZWJRTk9VbVNZTk90cFRsb0F5all3WTRhTlZVZ05teGtLNkpxVXREaDVPOGRVY3NzM3FwNjRlemI2VFlaM2ZLY3JqYlJYX1FhcGcyWkJGa25aTnZxdVd6QVBfYTZfbDk0aGFKMm93V3JFaWdyckhQakF2bFpqTE9OS3dRTFdMNUxNMlRaYS1ncXRlZl9Ld1N1YmdJRHgwV3E4MFFhWEUwa05DX21oSko2b2FXUG1aZmtmbWQ?oc=5","date":"2026-02-24","type":"regulatory","source":"globenewswire.com","summary":"ORYZON Receives European Medicines Agency Approval to - globenewswire.com","headline":"ORYZON Receives European Medicines Agency Approval to","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQZlotVXI3X2N4MzJiZHdnTGVPZlg1TFpmR2hWUlRBaWdZOUJCSnlQaTM5UGpxVHV3Q1ZjYjk5WDlha01qcFM2YzFsMGs5cWpjaVpOVExUdzRvYmdsTkRoaTZQNjV3T0syOV9ITnppNlp6cEgtS2czMFNLekd5UUd2S1JHNFdXeWFWbUZlTlBsNVR4aEdIVTA1X0RXRGRUcU1kZ2J2RHYzVmsxTUt1NWtVUG9PUHBCdFFoZHlFU2xwVTBrRDJkcEd4X1V4bDM1Z1BVV1llTTBVRkxGRzVEM0JPYlJ6TENyb1kyRmdYYjlsNzF3MmVoZU5FbWViWQ?oc=5","date":"2026-02-12","type":"pipeline","source":"globenewswire.com","summary":"ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS - globenewswire.com","headline":"ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-24","type":"pipeline","source":"simplywall.st","summary":"European Growth Companies With High Insider Ownership In September 2025 - simplywall.st","headline":"European Growth Companies With High Insider Ownership In September 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNYVZGb1d4SlV6bHhTQ0RSVURidk9lekxZR0JyZlM1OEFCcmNBcnpaNGZCZzdybERwZFNjb2VSSjJmWXJpdUMwbWMxZW93ZXY0SV8wUDRBSVRaaFRxeFpPNXFCZ3JqQUpwbEtWdFNEY2lPYURISVF2QmV4aG8zdmw0dlpxV0RFT3VnV29fRmdkdDd3WkVrM1VJaU5rb0J3aHdGbkhGeE0yRFM4clBOQWxGT0JaTFcxS3VlVHZzNHU1YjlhQlEtcG1OUjlzdEp1QjU5RlNBeXNlcHZJLVl6SVBONkdkTQ?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire","headline":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQcXYxaGRGaW1HdmhNRVhnZmU3eVY5aE9vbXRyNHN1YzZlUWNzeV91YWxVQlFXc0FjQ2ZRLXRSZ0FVMTluQkl2UjFtaFBUZ29RbE9hODl6Qk4teTVXYjZMNEFNMjRMZVA1VnQtOWRlSzl0c0MwdzdGdk43d0JfRFRWRFhFbFRJbnMxY1NCNndVal83YWQ2TnA1NkdVbzNZdi1qZ0Nra05UbFgtMVZ6N1RUVGtneWZ2VUNzVWV3bUZKS28waVNfRHpnZ2djV18xbHpobFhyMUU5ZnhJM2plRHd4aHN4M0p0Vi1hN1ZyOEUtOEJ2S1E?oc=5","date":"2024-10-24","type":"earnings","source":"globenewswire.com","summary":"ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024 - globenewswire.com","headline":"ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxOdGozQjRtZ2JCZUVkUG5OWWVtUEl6eTBBOVYyTzFPYVlUVjIxRFNBUFBtMktwU1NfbVVyLUU4QUFFV0Z1NE4xOHdOWTBMcU9YS1pSTGhLSXpwVUpjYmZZdElndWdhclVLa2NjMWlMazh3bDR3T2ZId3VfLXFzWEo2YnljRk9lREtTLTN5S1o3eXNXZlo5MzFiYXJIOTJCbnVlT3RUeHNtR2didVA2MzJfb2xhX1FsNEhRSEx1c1p3M09JcEs0M2QtYUlGcGdKaVl0TnQzV0lfR1Y0NEpuM0huT0kwUnBJUkVJbjNFanBZdEJpTjFqTzd6WW93el9pM2Y1M3FfYVNteV85cTlOdUpWTUE5UFdfNVlWTVdMbzZPQVdDeDNVMHUwejVCSzNpYWhwQ1BBdFo1WQ?oc=5","date":"2024-05-29","type":"deal","source":"globenewswire.com","summary":"ORYZON Selected as Associated Partner in the First - globenewswire.com","headline":"ORYZON Selected as Associated Partner in the First","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNd0xfQ0dxa0VhdGNvZ1pjd21Td2ZuSS0zbjNqMWtDU1dmNU5CLV8xUkFsdVR5TjJFQTBrdVdudjg0WGN4QUJrdmNJYnZ2TEVTVnFFTXFxQU5STWdKc21XbkNMM0JuWXpqUTNFVklKcUpzTk4yV21DS2lPR1Yxd0dERWUtc1ExOTRfcF84MWI0MFNiLS1ZclZKM0FBS3dUbndRWU4wLUhHM2xndFRFcHVKak52cVUxWS1MM0NlUUQ5NkF2UEJKY1ZtMTRZbkkxenFYVGstVUw3TnNvUHlaQkNpMlAxeXZwdl8wdkFvQVBmbEV2ZXk5YlYzSkV6dkJ2bm9rb2lGWmVJcEw2czgyZEJscFB2cUdrdlRXcllUbnZVVVNxSUx0M0x6YlA0Z0ZNZ29VTVpXbE9Tdw?oc=5","date":"2024-01-08","type":"trial","source":"globenewswire.com","summary":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - globenewswire.com","headline":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQM3BKWDI5QWVabl9QYVc4X2hmZTRGMFNvN2V0R2VpMlRZVkFCVDRZejFsWWV2eTZfXzhEMF9yMzVQZmx3akRXTEdLOWV4RjFYdEJfVG1XM2tVWS1CclUwbHNyUEo4TjZBR1JrRE9wYnhDT2xnN3hFZlp4NXRPY1I4UEttUkwyRmly?oc=5","date":"2023-10-27","type":"pipeline","source":"EU-Startups","summary":"101 Top Medical Startups and Companies in Spain (2021) - EU-Startups","headline":"101 Top Medical Startups and Companies in Spain (2021) - EU","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9XVHhhOEdWajhDamx1cHJFSzl0Y1VjamZ3d1N3bmRLal9ibDM3Y2M2eGprRzNNZ0Z3NDVaS1NXQWlXNEY0alFOMk1OQ3o1eUNqVTBlWA?oc=5","date":"2017-05-22","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Pharma Mar, S.A. (PHM.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Pharma Mar, S.A. (PHM.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":12,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}